Sage Therapeutics (SAGE) Stock Forecast, Price & News

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 17 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.

20 brokers have issued 12-month price targets for Sage Therapeutics' stock. Their SAGE share price forecasts range from $20.00 to $294.00. On average, they predict the company's stock price to reach $43.57 in the next twelve months. This suggests a possible upside of 119.0% from the stock's current price.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.

Sage Therapeutics' stock was trading at $38.14 at the beginning of 2023. Since then, SAGE shares have decreased by 47.8% and is now trading at $19.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our SAGE earnings forecast.

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Monday, August, 7th. The biopharmaceutical company reported ($2.68) earnings per share for the quarter, missing the consensus estimate of ($2.55) by $0.13. The biopharmaceutical company earned $2.47 million during the quarter, compared to analyst estimates of $2.94 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 49.82% and a negative net margin of 5,704.03%. The business's revenue for the quarter was up 64.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.13) EPS.

ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Simplify Propel Opportunities ETF (SURI), ALPS Medical Breakthroughs ETF (SBIO) and Alpha Architect U.S. Quantitative Momentum ETF (QMOM).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Sage Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.39%), Bellevue Group AG (5.20%), State Street Corp (3.84%), Dimensional Fund Advisors LP (2.87%), JPMorgan Chase & Co. (2.83%) and Geode Capital Management LLC (1.78%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends.

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAGE stock can currently be purchased for approximately $19.90.

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $1.19 billion and generates $7.69 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($9.92) on an earnings per share basis.

The company employs 689 workers across the globe.

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.